EP3659605A1 — Prevention and treatment of metastatic disease in thrombocytotic cancer patients
Assigned to Arovella Therapeutics Ltd · Expires 2020-06-03 · 6y expired
What this patent protects
The present invention relates to the use of the anti-megakaryocytic agent anagrelide or a therapeutically active metabolite thereof, in the prevention and/or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
USPTO Abstract
The present invention relates to the use of the anti-megakaryocytic agent anagrelide or a therapeutically active metabolite thereof, in the prevention and/or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
Drugs covered by this patent
- Subutex (Buprenorphine Hydrochloride) · Indivior
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.